US Broker Ratings

REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 226% Potential Upside in the Biotech Space

REGENXBIO Inc. (NASDAQ: RGNX) is a name making waves in the biotechnology sector with its innovative approach to tackling genetic disorders through gene therapy. As a clinical-stage biotech firm, REGENXBIO..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: A Biotechnology Pioneer with a 36% Upside Potential

Relay Therapeutics, Inc. (NASDAQ: RLAY) stands out in the biotechnology sector as a clinical-stage precision medicines company focusing on advancing small molecule therapeutic discovery in targeted oncology and genetic disease..

Evolus, Inc. (EOLS) Stock Analysis: Exploring a 263.94% Potential Upside in the Healthcare Sector

Evolus, Inc. (NASDAQ: EOLS), a prominent player in the healthcare sector, is drawing significant attention from investors with its potential upside of 263.94%. As a company specialized in the delivery..

Valneva SE (VALN) Stock Analysis: Exploring a Potential 119% Upside Amid Vaccine Innovations

Valneva SE (NASDAQ: VALN), a French biotechnology company specializing in prophylactic vaccines, is capturing the attention of investors due to its significant potential upside of 119.26%, as indicated by analyst..

Nurix Therapeutics, Inc. (NRIX): Analyst Ratings Signal a Potential 93% Upside for Biotech Innovator

For investors eyeing the biotechnology sector, Nurix Therapeutics, Inc. (NASDAQ: NRIX) presents an intriguing opportunity. This clinical-stage biopharmaceutical firm, headquartered in Brisbane, California, is pioneering advancements in cancer and inflammatory..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 162% Potential Upside

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a prominent player in the biotechnology sector, is currently turning heads with its impressive potential upside of 162.17%, according to recent analyst ratings. With a..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Challenges with a Steady Growth in Revenue

InnovAge Holding Corp. (NASDAQ: INNV), a prominent player in the healthcare sector, particularly within the medical care facilities industry, has been making headlines with its innovative approach to senior care...

Xencor, Inc. (XNCR) Stock Analysis: Navigating a 121.83% Potential Upside in the Biotech Sector

Xencor, Inc. (XNCR), a prominent player in the biotechnology industry, stands out with its promising potential upside of 121.83%, making it a stock worth considering for individual investors seeking exposure..

HealthStream, Inc. (HSTM) Stock Analysis: Navigating Potential 49% Upside in the Healthcare SaaS Market

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the Health Information Services industry, is drawing attention from investors with its strategic position in the burgeoning Software-as-a-Service (SaaS) sector tailored for..

CareDx, Inc. (CDNA) Investor Outlook: A 35% Upside Beckons in the Diagnostics Sector

CareDx, Inc. (CDNA) is a key player in the healthcare sector, specializing in diagnostics and research aimed at improving outcomes for transplant patients. Headquartered in Brisbane, California, CareDx provides a..

Immunome, Inc. (IMNM) Stock Analysis: Exploring a 62.72% Upside Potential in Biotech

Immunome, Inc. (NASDAQ: IMNM) is capturing investor attention with its impressive potential upside of 62.72%, according to recent analyst ratings. With a focus on developing innovative treatments for cancer through..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unveiling a 162% Potential Upside in the Biotech Arena

Investors with a keen eye on the biotechnology sector might find Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) a compelling addition to their portfolios. With a market cap of $1.41 billion, this..

Sionna Therapeutics, Inc. (SION) Stock Analysis: Exploring a 21.29% Potential Upside in Biotech Innovation

Sionna Therapeutics, Inc. (NASDAQ: SION), a burgeoning player in the biotechnology sector, is drawing significant attention from investors, driven largely by its impressive 21.29% potential upside based on current analyst..

Delcath Systems, Inc. (DCTH): Healthcare Innovator with 121% Upside Potential

Delcath Systems, Inc. (NASDAQ: DCTH) is capturing investor attention with its innovative approach to cancer treatment and a compelling potential upside of over 121%. Specializing in medical devices within the..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring an 80% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a biotechnology firm focused on developing treatments for chronic cough conditions, presents a compelling investment opportunity with an impressive potential upside of 80.45%. Situated within..

Zymeworks Inc. (ZYME) Stock Analysis: A 55% Upside Potential Awaits in the Biotechnology Sector

For investors with an eye on the healthcare sector, Zymeworks Inc. (NASDAQ: ZYME) presents a compelling opportunity within the biotechnology industry. Based in Middletown, Delaware, Zymeworks is making waves with..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 129% Potential Upside

Investors seeking opportunities in the healthcare sector might find Vir Biotechnology, Inc. (NASDAQ: VIR) an intriguing candidate, particularly given its robust analyst ratings and significant potential upside. As a clinical-stage..

Enliven Therapeutics, Inc. (ELVN): Analyst Consensus Points to a 19.57% Upside for This Biotech Stock

Enliven Therapeutics, Inc. (NASDAQ: ELVN) has been capturing significant attention in the biotechnology sector, with analysts unanimously rating it as a “Buy.” As a clinical-stage biopharmaceutical company, Enliven is focused..

Savara, Inc. (SVRA) Rating Update: Analysts Eye 94% Upside Potential with Lead Drug in Focus

Savara, Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company headquartered in Langhorne, Pennsylvania, is capturing the attention of investors with its promising pipeline in the treatment of rare respiratory diseases. With..

Avadel Pharmaceuticals plc (AVDL) Investor Outlook: Navigating Growth Amidst Analyst Caution

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company based in Dublin, Ireland, has been capturing investor attention with its robust revenue growth of 54.90%. Specializing in the development of specialty..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds